Altamira Therapeutics Ltd. (NASDAQ:CYTO) Short Interest Down 20.1% in June

Altamira Therapeutics Ltd. (NASDAQ:CYTO) was the recipient of a significant decline in short interest in June. As of June 15th, there was short interest totalling 102,900 shares, a decline of 20.1% from the May 31st total of 128,800 shares. Based on an average daily trading volume, of 1,930,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 4.6% of the shares of the stock are short sold.

Altamira Therapeutics Stock Up 9.9 %

NASDAQ:CYTO opened at $1.22 on Tuesday. The stock has a fifty day simple moving average of $1.44 and a 200-day simple moving average of $1.94. Altamira Therapeutics has a 52-week low of $1.05 and a 52-week high of $17.20.

Institutional Trading of Altamira Therapeutics

An institutional investor recently bought a new position in Altamira Therapeutics stock. Armistice Capital LLC purchased a new stake in Altamira Therapeutics Ltd. (NASDAQ:CYTO) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 829,000 shares of the company’s stock, valued at approximately $203,000. Armistice Capital LLC owned 11.86% of Altamira Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 1.91% of the company’s stock.

Altamira Therapeutics Company Profile

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.